Poseida Therapeutics, Inc.
PSTXNASDAQHealthcare
$9.50
+$0.00(+0.00%)
Market Cap$925933688
P/E Ratio—
52W High$9.67
52W Low$1.87
Poseida Therapeutics, Inc. (PSTX) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · PSTX · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2023-12 | 2022-12 | 2021-12 | 2020-12 | 2019-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $64.70M | $130.36M | $0.03M | $0.00M | $0.00M |
| Cost of Revenue | $156.77M | $5.17M | $4.55M | $2.59M | $1.19M |
| Gross Profit | ($92.07M) | $125.19M | ($4.52M) | ($2.59M) | ($1.19M) |
| Gross Margin %(computed) | -142.29% | 96.03% | — | — | — |
| Operating Expenses | |||||
| R&D Expenses | $156.77M | $152.90M | $0.14M | $0.10M | $60.39M |
| G&A Expenses | $37.44M | $37.54M | $0.04M | $0.02M | $18.46M |
| Total Operating Expenses | $194.21M | $190.44M | $0.17M | $0.13M | $78.85M |
| Operating Income | ($129.50M) | ($59.95M) | ($0.14M) | ($0.13M) | ($85.53M) |
| Operating Margin %(computed) | -200.15% | -45.98% | -452.69% | — | — |
| Interest Income | $0.00M | $0.00M | $0.00M | $3.51M | $1.55M |
| Interest Expense | $8.67M | $6.37M | $3.36M | $0.00M | $3.55M |
| Income Before Tax | ($123.32M) | ($63.46M) | ($0.12M) | ($0.13M) | ($86.53M) |
| Income Tax Expense | $0.11M | $0.54M | ($4.53M) | ($2.58M) | $0.00M |
| Net Income | ($123.43M) | ($64.00M) | $4.40M | $2.45M | ($92.64M) |
| Net Margin %(computed) | -190.76% | -49.10% | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-1.37 | $-0.89 | $0.07 | $0.04 | $-2.33 |
| Wtd Avg Shares | 90.19M | 71.91M | 62.18M | 58.40M | 39.73M |
| EBITDA | ($109.04M) | ($51.92M) | ($117.06M) | ($145.48M) | ($91.68M) |
| EBITDA Margin %(computed) | -168.52% | -39.82% | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · M
Explore more Poseida Therapeutics, Inc. data
About Poseida Therapeutics, Inc. (PSTX) Income Statement
Poseida Therapeutics, Inc. (PSTX) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2023, PSTX reported revenue of $0.06B, gross profit of ($0.09B) (gross margin -142.29%), and net income of ($0.12B) — a net profit margin of -190.76%.
Frequently asked questions
PSTX · 4 questionsPoseida Therapeutics, Inc. (PSTX) reported revenue of $0.06B for 2023, down 50.4% year-over-year.
PSTX revenuePSTX salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09